Abstract:<p>Antibody disulfide bond reduction has been a challenging issue in monoclonal antibody manufacturing. It could lead to decrease of product purity and failure to meet targeted product profile and/or specifications. More importantly, disulfide bond reduction could also impact drug safety and efficacy. Scientists across industry have been examining the root causes and developing mitigation strategies to address the challenge. In recent years, with the development of high titer mammalian cell culture processes to meet the rapidly growing demand for antibody biopharmaceuticals, disulfide bond reduction has been observed more frequently. Thus, it is necessary to continue evolving the disulfide reduction mitigation strategies and developing novel approaches to maintain high product quality. Additionally, in recent years as more complex molecules (such as bispecific and trispecific antibodies) emerge, the molecular heterogeneity due to incomplete formation of the interchain disulfide bonds becomes a more imperative challenging issue. Given the disulfide reduction challenges that biotech industry is facing, in this review, we provide a comprehensive scientific summary of the root cause analysis of disulfide reduction during process development of antibody therapeutics, mitigation strategies and its potential remediated recovery based on published papers. First, this paper intends to highlight different aspects of the root cause for disulfide reduction. Secondly, to provide a broader understanding of the disulfide bond reduction in downstream process, this paper discusses disulfide bond reduction impact on product stability, associated analytical methods for disulfide bond reduction detection and characterization, process control strategies as well as their manufacturing implementation. In addition, brief perspectives on the development of future mitigation strategies are also reviewed, including platform alignment, mitigation strategy application for the emerging new modalities such as bispecific and trispecific antibodies as well as using machine learning to identify molecule susceptibility of disulfide bond reduction. The data in this review are originated from the published papers.</p><p>This article is protected by copyright. All rights reserved.</p>

Identifying and modulating disulfide formation in the biopharmaceutical production of a recombinant protein vaccine candidate

Optimization and kinetic modeling of interchain disulfide bond reoxidation of monoclonal antibodies in bioprocesses

Streamlining the Characterization of Disulfide Bond Shuffling and Protein Degradation in IgG1 Biopharmaceuticals Under Native and Stressed Conditions

Bioproduction Platform to Generate Functionalized Disulfide-Constrained Peptide Analogues

Flavoenzyme-catalyzed Formation of Disulfide Bonds in Natural Products.

Antibody disulfide bond reduction and recovery during biopharmaceutical process development—A review

Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate

Novel method for production and purification of untagged pneumococcal surface protein A from clade 1

In-Depth Characterization of a Re-Engineered Cholera Toxin Manufacturing Process Using Growth-Decoupled Production in Escherichia coli

Electrocatalytic Reduction of Disulfide Bonds in Antibodies

Development and validation of a targeted LC-MS/MS quantitation method to monitor cell culture expression of tetanus neurotoxin during vaccine production

In Situ Capture of Bacterial Toxins for Antivirulence Vaccination

Systematic computer-aided disulfide design as a general strategy to stabilize prefusion class I fusion proteins

A Thermostable Dissolving Microneedle Vaccine with Recombinant Protein of Botulinum Neurotoxin Serotype A

Mechanism of antibody reduction in cell culture production processes

On-Demand Thio-Succinimide Hydrolysis for the Assembly of Stable Protein-Protein Conjugates

Development and characterization of a novel neutralizing scFv vectored immunoprophylaxis against botulinum toxin type A

Development and scale-up of a commercial fed batch refolding process for an anti-CD22 two chain immunotoxin

Rapid Identification of Disulfide Bonds and Cysteine-Related Variants in an IgG1 Knob-into-Hole Bispecific Antibody Enhanced by Machine Learning

A production platform for disulfide-bonded peptides in the periplasm of Escherichia coli

Determination of degradation for sulfo-SIAB, SM(PEG)2, and sulfo-GMBS by RPLC-UV analysis